Skip to main content
DYAI logo

DYAI · Dyadic International Inc

Track DYAI — free
$0.29 -0.02 (-6.05%)
Market Cap
$12.46M
Shares
40.09M
Volume · Nov 19 139.99K Avg daily vol (3M) 140.28K

Price & Indicators

 

Key stats

Close
$0.31
Open
$0.32
Day range
$0.30–0.34
52-week closing range
$0.31–1.47
Average volume, 30 days
92K
Short interest
83K · 0.2% of shares · 1.0 days
Short volume, last session
68%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 13
Price history
Jan 2020 to Nov 2026

Up next

Mar 24, 2027 Est · unconfirmed · in 18 wks

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
First direct sales debut amid going-concern doubt

Dyadic International recorded first direct commercial product sales; management also cited substantial doubt about its ability to continue as a going concern.

Revenue $449.1K ▼ 61.4% Net loss $1.36M Diluted EPS -$0.04
Read from the MD&A section
3 source passages
Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) d/b/a Dyadic Applied BioSolutions, is a global biotechnology platform company headquartered in Jupiter, Florida, with operations in the United States and the Netherlands. During the third quarter, Dyadic recorded its first direct commercial product sales, primarily of recombinant transferrin and DNase I. As of September 30, 2026, our management has concluded that there is substantial doubt about our ability to continue as a going concern, which depends upon our obtaining necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 12
First direct protein sales as quarterly revenue falls 61.4%

Dyadic International, Inc. recorded its first direct commercial protein sales in the quarter ended September 30, 2026, while revenue fell 61.4% to $449,101. Net loss was $1,357,041, and its cash position was $6,046,083 as of September 30, 2026.

Financial results
5 source passages
Dyadic International, Inc. (NASDAQ: DYAI), doing business as Dyadic Applied BioSolutions (the “Company” or “Dyadic”), a biotechnology company developing and commercializing precision-engineered, animal-free recombinant proteins and enzymes, today reported financial results for the third quarter ended September 30, 2026. During the third quarter, Dyadic recorded its first direct commercial product sales, primarily of recombinant transferrin and DNase I. Total revenue for the three months ended September 30, 2026, was $449,101, representing a decrease of $715,516 or 61.4% compared to $1,164,617 for the three months ended September 30, 2025. Net loss for the three months ended September 30, 2026 was $1,357,041 or $(0.04) per share, compared to $1,976,012 or $(0.06) per share for the same period a year ago. Cash Position: As of September 30, 2026, cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interest, were $6,046,083 compared to $8,587,289 as of December 31, 2025. Open the document at this passage
Nov 12
Earnings call
Revenue $449,000, down 61%, first direct protein sales

Revenue was approximately $449,000, down 61%, with loss of approximately $1.4 million ($0.04 per share) and about $6 million in cash. Dyadic booked first direct protein sales and expects a $225,000 payment in the fourth quarter from Enzymes' chymosin sale.

5 source passages
Total revenue for the three months ended September 30, 2026 was approximately $449,000 compared to approximately $1,165,000 for the third quarter of 2025. The decrease of 61 percent was driven by a $538,000 decline in grant revenue Net loss for the quarter was approximately $1.4 million, or $0.04 per share, compared to approximately $2 million, or $0.06 per share for the third quarter of 2025. We ended the third quarter with approximately $6 million in cash, cash equivalents, restricted cash, and investment-grade securities, including accrued interest. during the third quarter, Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNA swan. In November, Enzymes informed us that its first commercial sale of DAPOBIS-produced camel chymosin occurred in October. As a result, we expect to receive a $225,000 contractual payment and recognize the associated revenue during the fourth quarter. Open the document at this passage
Sep 25
Current report 8-K
Delisting notice or listing transfer

Dyadic International received Nasdaq deficiency notices for failing the minimum $1 per share bid price and $35 million Market Value of Listed Securities requirements. It has until March 24, 2027 to regain compliance, and may appeal any delisting determination.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.09M
Trailing 12 months
Net income (TTM)
−$7.00M
Trailing 12 months
Revenue growth YoY
-61.4%
Year over year
Operating margin
-236.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.4%
Year over year · more shares
Price change (1Y)
-66.6%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Commercial and technical milestones included first direct protein sales, expanded distribution, a $225,000 chymosin milestone, advancing alpha-lactalbumin collaboration, and rapid C1 antibody and vaccine development results. However, revenue fell 61.4%, cash declined to $6,046,083, operating cash burn remained approximately $5.3 million for nine months, commercial sales remained modest, and management disclosed going-concern uncertainty.

Bullish
  • + Dyadic recorded its first direct commercial protein product sales and expanded third-party distribution.
  • + Inzymes achieved the first commercial sale of the second Dapibus-produced chymosin, triggering a $225,000 milestone payment expected as fourth-quarter revenue.
  • + C1 achieved antibody yields of approximately 12.1 g/L for RSV and 13.2 g/L for malaria.
  • + C1 produced two ebolavirus antigens in approximately 15 days and a monoclonal antibody in approximately seven weeks.
  • + The BRIG BIO and Strive Nutrition collaboration is advancing bovine alpha-lactalbumin toward potential commercial-scale supply.
  • + Quarterly net loss narrowed to approximately $1.4 million, or $0.04 per share, from approximately $2 million, or $0.06 per share.
Bearish
  • − Third-quarter revenue fell 61.4% to $449,101 from $1,164,617 year over year.
  • − Cash, restricted cash, and investment-grade securities declined to $6,046,083 from $8,587,289.
  • − Net cash used in operating activities was approximately $5.3 million for the first nine months, and management expects similar cash usage.
  • − Management disclosed substantial doubt about the company's ability to continue as a going concern.
  • − Early commercial sales remained modest and evaluation timelines were longer than anticipated.
  • − Limited capital has constrained inventory placement and slowed the research product business.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −57%
below
Price vs 50-day avg −22%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −60%
trailing
YTD return −67%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.21% of shares out · ▼ -57.3% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
42 holders — near 3-yr high, broad support
Squeeze score 17
low risk · 0–100
Fundamentals
Weak
Revenue growth −12%
Y/Y
EPS growth −15%
Y/Y
Buyback $2.2M
remaining
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −79%
past year
ATR 12.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 13, 2026
Milestone payment · fourth quarter of 2026 $225,000
Previous outlook earlier release · from the Earnings Call filed Nov 12, 2026

Still-open targets the latest release did not restate under the same label.

Associated revenue · during the fourth quarter $225,000

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−57% Bearish
Price vs 50-day avg
−22% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.21% of shares out · ▼ -57.3% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
42 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -57% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
from plasmid to C-tag-purified protein 15 third quarter —
production yields of approximately 12.1 g/L for RSV monoclonal antibody RSM01 12.1 third quarter —
production yields of approximately 12.1 g/L for RSV monoclonal antibody RSM01 and 13.2 g/L for m 13.2 third quarter —
Pilot-scale process improvements increased recombinant human transferrin productivity 80% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DYAI
Dyadic International Inc
this stock
$12.46M -66.9% -11.6% — 0.2%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
42
% held
18.9%
Net QoQ
+3.0M sh
Top holder
Empery Asset Management,…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
83.2K
Days to cover
1.0d
Change
-111.5K sh
View
Short Volume
Short vol %
68%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
248
Value
$109
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
73.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$3.1M
Net income (FY)
$-7.4M
EPS diluted
$-0.23
View
Buybacks
Authorized
$5.0M
Remaining
$2.2M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
22

Dyadic International, Inc. recorded its first direct commercial protein sales in the quarter ended September 30, 2026, while revenue fell 61.4% to $449,101. Net loss was $1,357,041, and its cash position was $6,046,083 as of September 30, 2026.

View
Proposed Sales
Value
$539.3K
Shares
364.4K
Filed
Jul 21, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
DYADIC ANNOUNCES THIRD QUARTER 20…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
DYAI -11.2% -22.7% -60.2% -18.3% -66.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -5.8% -16.4% -54.5% -13.0% -71.9%

Capital returns

Buyback program · as of Aug 31, 2018
Authorized
$5.00M
Spent (derived)
$2.84M
Remaining
$2.16M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1213809 CUSIP 26745T101 13F (30d) 41 filings 41 filers Visit website Investor relations